BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside the kinase domain in the neighboring linker, SH2,...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Sherbenou, Daniel W., Hantschel, Oliver, Kaupe, Ines, Willis, Stephanie, Bumm, Thomas, Turaga, Lalita P., Lange, Thoralf, Dao, Kim-Hien, Press, Richard D., Druker, Brian J., Superti-Furga, Giulio, Deininger, Michael W.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2010
主題:
Myeloid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2995357/
https://ncbi.nlm.nih.gov/pubmed/20519627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-10-183665
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍